CBIO
Catalyst Bio shares bashed as neutralizing antibodies force investigators to freeze hemophilia cohort work
The two patients were able to resume treatment with their prescribed IV FIX prophylaxis therapies.
On the bright side, the South San Francisco-based company also gave a thumbs up to the efficacy they’ve been seeing
https://endpts.com/catalyst-bio-shares-sideswiped-as-neutralizing-antibodies-force-investigators-to-freeze-hemophilia-cohort-work/
Otros comentarios interesantes:
The stock had run from $3 to $35 on this phase 1/2 trial. The big fall not that surprising considering this the run.
$
CBIO valuation adjustment in progress based on their Hemo pipeline.
Not exactly clear what the antigen was as company states other hemophilia factors were not affected (that would have been BAD as those pts would lose all treatment options)
CEO said no read thru yet from CB 2679d to their 2nd program MarzAA (data next month). Different mutations, molecules, dosing, population, drug product quality, manufacturer
1 patient developed neutralizing antibody (was able to resume treatment). They'll fix it. Plus, MarzAA data in July Bounce this week
18-21 julio habrá update en no me acuerdo qué presentación
Y pasado mañana tiene JMP Securities 2018 Life Sciences Conference at 12:00 p.m. EDT on Thursday, June 21, 2018
«Después de nada, o después de todo/ supe que todo no era más que nada.»